Valbiotis Stock

Valbiotis ROE

The Return on Equity (ROE) of Valbiotis (ALVAL.PA) as of Aug 17, 2026 is -96.69 %. In the previous year, Return on Equity (ROE) was -37.59 % — a change of 157.21% (lower).

ROE

-96.69 %

YoY

157.21%

Last updated:

In 2026, Valbiotis's return on equity (ROE) was -96.69 %, a 157.21% increase from the -37.59 % ROE in the previous year.

Access this data via the Eulerpool API

Valbiotis Stock analysis

What does Valbiotis do? Valbiotis SA is a French company specializing in the research and development of new and innovative treatment options based on plant-derived ingredients. The company was founded in 2014 by Sebastien Peltier, an experienced employee in the pharmaceutical industry, who wanted to search for new and effective therapeutic possibilities. Valbiotis' business model is based on identifying and utilizing new plant-derived ingredients to develop therapies that cater to market needs. The company works closely with various partners, universities, and research organizations to ensure that their products are based on the latest scientific findings. One of Valbiotis' main areas of focus is the development of products to support metabolism and metabolic health. They utilize solutions based on a plant-derived ingredient called TOTUM-63, which aims to treat and prevent risk factors such as obesity, insulin resistance, and metabolic diseases like Type 2 diabetes. Valbiotis has also established a comprehensive research department to explore further applications for their plant-derived ingredients, including cardiovascular diseases and neurodegenerative diseases like Alzheimer's. One of Valbiotis' most well-known products is TOTUM-63, a plant-derived ingredient that has positive effects on metabolism. TOTUM-63 consists of four different plant-derived ingredients and is intended to restore balance to metabolism and support the body in combating risk factors such as obesity and Type 2 diabetes. The company is currently seeking further promising applications for TOTUM-63. Valbiotis has also formed partnerships with major pharmaceutical companies such as Nestlé Health Science and Nestlé Research to fund their research and optimize the use of their plant-derived ingredients. Additionally, Valbiotis collaborates with various universities and research institutions to incorporate the latest scientific findings into their products. Overall, Valbiotis is one of the most promising companies in the pharmaceutical industry focused on plant-derived ingredients. The company has developed a wide range of products and applications and works closely with various partners to develop innovative therapy options based on plant-derived ingredients. Valbiotis is well-positioned to achieve further growth in the future and treat and prevent diseases in a new way. Valbiotis is one of the most popular companies on Eulerpool.

ROE Details

Decoding Valbiotis's Return on Equity (ROE)

Valbiotis's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Valbiotis's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Valbiotis's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Valbiotis’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Valbiotis stock

Return on Equity (ROE) of Valbiotis is -96.69 % in 2026.

Return on Equity (ROE) of Valbiotis changed from -37.59 % to -96.69 %, representing a 157.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Valbiotis since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Valbiotis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Valbiotis

All Key Metrics — Valbiotis